Feature | Mammography | May 14, 2018

FDA's MQSA Accreditation Bodies Approved for Tomosynthesis Accreditation

Three states and the American College of Radiology are now certified to accredit DBT systems

FDA's MQSA Accreditation Bodies Approved for Tomosynthesis Accreditation

Image courtesy of Fujifilm.

May 14, 2018 — On April 9, 2018, the U.S. Food and Drug Administration (FDA) announced that all four of its Mammography Quality Standards Act (MQSA) accrediting bodies are approved to accredit digital breast tomosynthesis (DBT) systems. This includes the states of Arkansas, Iowa and Texas, and the American College of Radiology (ACR).

In the medical device world, the constant evolution of technology continues to provide new and improved diagnostic and therapeutic tools, and the mammography world is no exception. On Feb. 11, 2011, the fourth generation of mammography technology emerged with FDA’s approval of the first DBT unit for U.S. marketing. At that time, just like when the first full field digital mammography (FFDM) unit was approved for marketing in January 2000, the FDA’s approved accrediting bodies (ABs) did not have standards developed or processes in place to accredit a new technology that was just introduced to the mammography community. Therefore, the FDA had to develop a stop-gap, temporary program — namely the FDA Certificate Extension Program. In the absence of accreditation, this program’s purpose was to provide a temporary way for new technology approved for marketing to be legally used under the MQSA, so that it could benefit patients while accreditation programs were being developed.

The MQSA mandates that facilities be accredited. Once ABs are ready to accredit a new technology, apply to FDA, and are approved, the transition from a certificate extension program to an accreditation program occurs. Such was the case with FFDM in February of 2003 and now again for DBT.

The FDA has worked and continues to work closely with the accrediting bodies to assist facilities with this transition. Individual accrediting bodies have established their own accreditation procedures and transition mechanisms within the confines of the MQSA requirements for accreditation. The FDA continued to accept applications up until April 6, 2018. Any facility granted an extension of its certificate to include the use of a DBT unit to date, or who is granted one on an application received by FDA by April 6, can continue to use its existing DBT unit(s) under that certificate extension while transitioning to being accredited by its accreditation body. If a facility with a current DBT certificate extension adds a new unit and wants to use the DBT modality on the new unit, the facility must now apply to its accreditation body to have that new unit accredited. All other facilities, and those certificate extension facilities that acquire DBT units after the April 6, 2018 cutoff date, must contact their respective ABs to apply for accreditation.

Although housed in a single unit, due to the differences in technology between FFDM and DBT, the FFDM and DBT components of the mammography system need to be accredited as two separate units if the facility uses the DBT component in clinical practice. And even if a facility uses only the DBT component of a mammography system, and not the FFDM mode, both the FFDM and DBT systems must be accredited, as accreditation of the DBT modality relies on documenting the proper functioning of certain aspects of the FFDM system. As when the Certificate Extension Program was in effect, both the FFDM and DBT portions of a unit will each individually require inspection during the annual MQSA inspection process.

To further assist facilities with the DBT accreditation process, the table below summarizes the system components, quality control (QC) tests and new modality training requirements that are evaluated during the accreditation process:

Facility System Facility Intended Use of System Accredit FFDM System? Accredit DBT System? Required Quality Control (QC) Personnel training Requirements
FFDM system with DBT capability FFDM (2-D) ONLY Yes No FFDM QC Only 8 hours of FFDM training only
FFDM (2-D), DBT (3-D) Yes Yes

FFDM OC

DBT QC

8 hours of FFDM training and 8 hours of DBT training
DBT (3-D) ONLY Yes Yes

FFDM QC

DBT QC

8 hours of FFDM training and 8 hours of DBT training
DBT Only System Currently, there are no DBT (3-D) systems approved for U.S. marketing that do not have an FFDM (2-D) component

As noted in the table above, all personnel who perform DBT exams (technologists), interpret DBT images (interpreting physicians) or evaluate DBT units (medical physicists) must have at least 8 hours of training in FFDM and 8 hours of training in DBT. Facilities are required to complete the required quality control testing depending on the clinical use of the unit.

While there was no charge for the temporary FDA Certificate Extension Program, facilities will now incur fees for DBT accreditation, as they do for other types of mammography accreditation. Fees are set by each AB and vary among them. The justifications for each AB’s fees are evaluated and approved by the FDA.

The accrediting bodies are the best source of information about the DBT transition to accreditation and the specifics of their DBT accreditation requirements and processes; their links are provided below:

For more information: www.fda.gov

 

Related Content

QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018
News | Ultrasound Women's Health | November 19, 2018
QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (...
Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of AreYouDense.org.

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
Feature | Breast Imaging | November 07, 2018 | By Jeff Zagoudis
Breast imaging technology has experienced major growth over the last decade or so, and a new report suggests the mark
Philips’ Compressed SENSE technology helps shorten MRI exams by eliminating redundant radiofrequency signals from the acquisition phase. The software reconstructs any missing  information to maintain high image quality. (Images courtesy of Philips/University Hospital Cologne)

Philips’ Compressed SENSE technology helps shorten MRI exams by eliminating redundant radiofrequency signals from the acquisition phase. The software reconstructs any missing information to maintain high image quality. (Images courtesy of Philips/University Hospital Cologne)

Feature | Breast Imaging | November 05, 2018 | By Jeff Zagoudis
The incidence of breast cancer is rising globally, with an estimated 1 in 8 women diagnosed in their lifetime and 40,...
Deaconess Health System Chooses Sectra as Enterprise Imaging Vendor
News | Enterprise Imaging | November 02, 2018
International medical imaging information technology (IT) and cybersecurity company Sectra will install its enterprise...
Volpara Enterprise Cloud Reaches 1 Million Mammograms Stored
News | Mammography | October 31, 2018
Volpara Solutions announced that the data stored in the Volpara Enterprise cloud now exceeds 1 million mammographic...